| Overview |
| bs-2903R |
| ARHI Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ARHI |
| 131-229/229 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 9077 |
| O95661 |
| Cell membrane |
| ARHI; NOEY2; GTP-binding protein Di-Ras3; Distinct subgroup of the Ras family member 3; Rho-related GTP-binding protein RhoI; DIRAS3; RHOI |
| ARHI contains a highly conserved GTP-binding domain, a putative effector domain distinct from that of RAS and RAP proteins, and a C-terminal membrane localization motif. ARHI mRNA is detected in all normal breast and ovarian epithelial cell cultures tested, as well as in normal ovary, heart, liver, pancreas and brain however ARHI expression is down-regulated in breast and ovarian tumors. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz